What were the key takeaways on trials from ASH 2019?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, Know AML were pleased to speak to Agnieszka Wierzbowska, Copernicus Memorial Hospital, Lodz, PL. We asked Agnieszka Wierzbowska: What were the key messages from the most promising trials presented at ASH?

Agnieszka Wierzbowska discusses the anticipated results from the QUAZAR AML-001 study, that was dedicated to examining the role of maintenance chemotherapy in treating elderly patients with acute myeloid leukemia. She also talks about the importance of cytogenetic stratification to guide patient treatment, so that patients can receive targeted therapy. She explains that this approach has benefited patients overall survival.